tirzepatide va zepbound (Tirzepatide) for Weight Loss Weight-loss drug Zepbound resolves sleep

In a head-to-head trial against liraglutide, tirzepatide reduced measured food intake and craving more despite lower GLP-1 occupancy

Notirzepatide is not FDA-approved as a tablet or pill

People who continued to take the medication lost an additional 5 percent of their original body weight, for a total average weight loss of 25 percent over the 88-week study

Regular monitoring identifies when adjustments become necessary

"GLP-1 Weight Loss Drug Demonstration Begins July 2026"

Klinic's team navigates the challenging waters of prior authorization for tirzepatide in California , ensuring that you can focus on your health rather than paperwork